Rethinking Oral Minoxidil: Distinguishing the Hair-Growth Window from the Cardiovascular Threshold

Oral minoxidil, originally developed for hypertension, is increasingly used off-label for hair disorders. Its cardiovascular effects are driven by peak plasma levels, with adverse effects like tachycardia occurring at concentrations above 20 ng/mL. In contrast, hair growth effects are mediated by minoxidil sulfate at much lower concentrations, around 1.6 ng/mL, and rely on sustained exposure rather than peak levels. This pharmacokinetic–pharmacodynamic separation is crucial for optimizing dosing, as lower doses can promote hair growth without significant cardiovascular risks. Understanding these differences is essential for safe and effective use in treating hair disorders.